Business

Alexza Pharmaceuticals and Spanish pharmaceutical company Grupo Ferrer International have formed a partnership to register, distribute, and promote the Adasuve Staccato loxapine inhaler for the treatment of agitation in patients with schizophrenia or bipolar disorder in Europe, Commonwealth of Independent States countries, and Latin America. The deal includes a $10 … [Read more...] about Alexza teams with Grupo Ferrer on Staccato loxapine inhaler

Swiss vaccine developer Mymetics Corporation has reclaimed an intranasal influenza vaccine that it had licensed to Solvay prior to Solvay's acquisition by Abbott Laboratories. Solvay had conducted a Phase 1 trial that found the vaccine to be well tolerated and safe and had made a milestone payment to Mymetics before stopping work on the project. Mymetics CFO Ronald … [Read more...] about Mymetics reclaims intranasal flu vaccine that had been licensed to Solvay

Only about a month after entering the nasal delivery device market, Bespak has announced a second contract for development of an intranasal device. The company says that "a major global manufacturer of generic medicines" has awarded Bespak a contract for both development of its Unidose nasal drug delivery device for an undisclosed application and for manufacturing and … [Read more...] about Second nasal delivery device contract for Bespak

The board of directors of contract research organization PPD has approved a $3.9 billion all cash deal which will take the company private after its acquisition by the Carlyle Group and Hellman & Friedman. PPD offers formulation development and analytical services for a wide variety of OINDPs, including DPIs, MDIs, inhalation solutions, and nasal aerosols. The deal, … [Read more...] about PPD agrees to be acquired for $3.9 billion

Graceway Pharmaceuticals, which manufactures the MaxAir Autohaler pirbuterol acetate MDI, one of the last remaining CFC-propelled metered dose inhalers, has agreed to sell all of its assest to Galderma, a " company focused exclusively on meeting the needs of dermatology patients and physicians." The MaxAir inhaler is scheduled for phase out two years from now, with a … [Read more...] about Manufacturer of MaxAir Autohaler purchased by dermatology-focused company

Marina Biotech (formerly MDRNA/Nastech) is offering intellectual property related to intranasal formulations of rapid-acting insulin and of parathyroid hormone (PTH) for the treatment of osteoporosis for sale through ICAP Patent Brokerage. ICAP has recently handled a number of portfolios related to inhalation and nasal delivery, offering several at live auction in … [Read more...] about Intranasal insulin and PTH formulations for sale

MannKind Corporation has announced a proposed offer of senior secured discount notes, due 2017, that would yield approximately $370 million. The company says that it would use the money to complete Phase 3 clinical trials of its Afrezza inhaled insulin, to prepare for commercialization of the product, and for work on its manufacturing plant in Danbury, CT, among other … [Read more...] about MannKind looking to raise $370 million for continued development of Afrezza

Novartis has launched its TOBI Podhaler tobramycin dry powder inhaler in the UK. The DPI, for the treatment of P. aeruginosa infections in cystic fibrosis patients. The CF Trust responded to the launch on its website, noting "This is the first ever antibiotic pod haler and is a development the CF Trust welcomes." Read a brief article. … [Read more...] about TOBI Podhaler DPI launched in UK